Press Releases
VALENCIA, Spain, June 02, 2024 (GLOBE NEWSWIRE) -- Allergic diseases cost between 1,823€ and 6,656€ per patient per year if we only consider the direct costs derived from healthcare, according to a study of the data collected through the European HEAD registry promoted by the EAACI, which is holding its congress at the Feria de Valencia until Monday, June 3.
“Allergic diseases and asthma are among the most common chronic diseases worldwide and account for a... (continue reading...)
SAN FRANCISCO, June 2, 2024 /PRNewswire/ -- FrogData (www.frogdata.com), the trailblazer in data-driven decision-making solutions for automotive dealerships, today announced a significant upgrade to its pioneering Artificial Intelligence (AI) Factory. This enhancement introduces new solutions focused on Used Car Pricing, Service Management, and New Car Sales Negotiation, further empowering dealerships to optimize their operations and profitability.
... (continue reading...)SAN FRANCISCO, June 2, 2024 /PRNewswire/ -- izmostock (www.izmostock.com), a leader in automotive imagery with over twenty years of global experience, today announced the launch of its revolutionary solution tailored specifically for the operational leasing sector. This new offering is set to transform the digital landscape of automotive leasing by providing high-quality, standardized vehicle images essential for online platforms.
As the summer season approaches, Ulike, a leading innovator in at-home beauty solutions, unveils the perfect companion for beach adventures: the Ulike Air 10. Designed to help you achieve smooth, nearly hair-free skin effortlessly, ensures you're ready to hit the beach with confidence and style.
—
Key Features of the Ulike Air 10:
In the context of the global growing demand for clean energy, the Pse.USDT platform has emerged, combining photovoltaic solar technology with the stability of USDT, aiming to promote the development of the global sustainable energy market. This platform stems from a profound understanding of the current energy market, especially the immense potential in the renewable energy sector. As blockchain technology matures in energy transactions, Pse.USDT is dedicated to... (continue reading...)
More Press Releases
View Older Stories-
TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial
-
GIGABYTE Partners with NVIDIA on RTX AI PCs Supporting ACE NIM and Digital Human Technology
-
Miami Beach Inspires this Summer with Film, Fashion and Music Experiences
-
CatalYm Reports Impressive and Lasting Responses Including Multiple Complete Responses in Heavily Pretreated, Late- to Last-Line Metastatic NSCLC, Urothelial and Hepatocellular Cancer Patients Treated
-
Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting
-
Rokid AR Lite Crowdfunding Surpasses $600,000 with One Day Left for Early Bird Price of $479
-
KFSHRC Successfully Treats Severe Case of "Xanthoma" After 26 Years of Suffering
-
KFSHRC Successfully Treats Severe Case of "Xanthoma" After 26 Years of Suffering
-
Flash News: OKX Now Supports Wormhole Protocol's W Token on Ethereum Mainnet
-
Flash News: OKX Now Supports Wormhole Protocol's W Token on Ethereum Mainnet
-
Discovery of World War II fighter plane sets path for first U.S.-Papua New Guinea Sister City
-
Linker Vision to Accelerate Vision AI Adoption Across Enterprise Applications with Large Vision Models, in Collaboration with NVIDIA
-
Belantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma
-
Seer Technology Access Center Provides Unprecedented Scale and Depth of Coverage for PrognomiQ’s Early Cancer Detection Study
-
ConcertAI to Advance Translational and Clinical Development Solutions in Collaboration with NVIDIA
-
Boomco (BOOM) Is Now Available for Trading on LBank Exchange
-
ASRock Rack Launches New Servers Supporting the NVIDIA Blackwell Architecture at COMPUTEX 2024
-
Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)
-
MEDSIR's PRIMED Study Shows Promising Results for Preventing Sacituzumab Govitecan related Side Effects in the Treatment of HER2-negative Advanced Breast Cancer
-
Flamingo Therapeutics Presents Poster at ASCO 2024 on Phase II PEMDA-HN Trial for Head and Neck Squamous Cell Carcinoma (HNSCC)
-
Precede Biosciences Presents New Data at ASCO 2024 Demonstrating Accurate HER2 Status Detection Across Multiple Cancers and the Ability to Quantify ER Pathway Activation in Breast Cancer from a Simple
-
ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer
-
Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 The
-
The Curious Journey of Qurious Media Singapore: Revolutionizing Digital Marketing for Small Businesses
-
GTS Nordic Expands with North Carolina Office to Meet Rising Demand for Compliant Employment Solutions in the United States
-
BIIB INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
Federal Government Authorizes Institute of Information Management to Certify Data Protection Professionals in Nigeria
-
Tolmar Announces Results From Inaugural Landmark Survey of US Physicians To Assess Current State of Testosterone Replacement Therapy (TRT) and the Impact on Practices and Patient Care
-
Tempus Introduces New HER2 & FOLR1 Testing Solutions to Support Personalized Patient Care
-
Hour One Enables Life-Like Cinematic Avatar of NVIDIA CEO Jensen Huang at Computex 2024
-
Introducing Red Kale Medley, a Mix of Baby Red and Green Kale Complemented by B&W’s Signature Watercress
-
Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024
-
ZT Systems Announces ACX200 Solutions Featuring NVIDIA GB200 Grace Blackwell Superchips for Next-Generation Accelerated Computing
-
NVIDIA Enables Real-Time Healthcare, Industrial and Scientific AI Applications at the Edge With Enterprise Software Support for NVIDIA IGX With Holoscan
-
NVIDIA Robotics Adopted by Industry Leaders for Development of Tens of Millions of AI-Powered Autonomous Machines
-
Robotic Factories Supercharge Industrial Digitalization as Electronic Makers Adopt NVIDIA AI and Omniverse
-
Bio-Thera Solutions Presents Clinical Data for BAT8006 (Folate Receptor-alpha-ADC) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
NVIDIA Brings AI Assistants to Life With GeForce RTX AI PCs
-
Computer Industry Joins NVIDIA to Build AI Factories and Data Centers for the Next Industrial Revolution
-
NVIDIA Supercharges Ethernet Networking for Generative AI
-
Trend Micro to Secure AI-Enabled Private Data Centers Worldwide
-
Denodo Opens ME Regional Head Office in Kingdom of Saudi Arabia to Meet Growing Demand for Data Management and AI
-
Vention to democratize industrial automation using NVIDIA AI technologies
-
Denodo Integrates NVIDIA NIM Inference Microservices to Accelerate and Optimize AI Capabilities for Enterprises
-
GDRX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that GoodRx Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Case
-
NVIDIA NIM Revolutionizes Model Deployment, Now Available to Transform World’s Millions of Developers Into Generative AI Developers
-
NVIDIA Releases Digital Human Microservices, Paving Way for Future of Generative AI Avatars
-
IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo
-
ENHERTU® Demonstrated a Median Progression-Free Survival of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy
-
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lin